Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600178 · ClinicalTrials.gov registry record · Phase 1
Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)
A Phase 1 study of Coronary Microvascular Disease and Coronary Microvascular Dysfunction (CMD), sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06600178 is a Phase 1 study of Coronary Microvascular Disease and Coronary Microvascular Dysfunction (CMD) that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06600178, a Phase 1 study of Coronary Microvascular Disease and Coronary Microvascular Dysfunction (CMD), is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are: Aim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease. Aim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR. AIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo Participants will: * Take study drug or placebo for 12 weeks * Stress Cardiac magnetic resonance imaging * 12 lead electrocardiograms * Complete questionnaires
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brezavvy 20Mg Oral Tablet
Study Locations (1)
Virginia
- UVA Health - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06600178
The ClinicalTrials.gov registry entry for NCT06600178 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Coronary Microvascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06600178 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06600178 about?
NCT06600178 is a clinical study titled "Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)". The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are: Aim 1: Test the hypothesis that Sodiu...
What is the current status of trial NCT06600178?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-06-27. Estimated completion is 2026-10.
What conditions does trial NCT06600178 study?
This clinical trial studies the following conditions: Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD), Angina Patients With Non-obstructive Coronary Artery Disease.
What interventions are being tested in trial NCT06600178?
The interventions under investigation include: Placebo (DRUG), Brezavvy 20Mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT06600178?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600178 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Microvascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Coronary Microvascular Disease
All registered trials for this condition
Coronary Microvascular Dysfunction (CMD)
All registered trials for this condition
Virginia
All trials with a study site in Virginia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.